(Q38207760)

31 August 2017

title

Adalimumab in the treatment of immune-mediated diseases (English)

1 reference

31 August 2017

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Corrado Blandizzi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Roberto Caporali

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Rolando Cimaz

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Andrea Marcellusi

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Carlo Salvarani

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

A Marchesoni

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

A Armuzzi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

S Chimenti

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

L Cimino

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

P Gionchetti

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

G Girolomoni

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

P Lionetti

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

F S Mennini

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

1 January 2014

1 reference

International Journal of Immunopathology and Pharmacology

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

1 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

33-48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Detecting shared pathogenesis from the shared genetics of immune-related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

New IBD genetics: common pathways with other diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Psoriasis associated with ulcerative colitis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Connections between psoriasis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Rheumatoid arthritis associated with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california-managed care organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Association of paediatric inflammatory bowel disease with other immune-mediated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Successful treatment with adalimumab in a patient with coexisting Behçet's disease and ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Prevalence of and annual ambulatory health care visits for pediatric arthritis and other rheumatologic conditions in the United States in 2001-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in wisconsin: a statewide population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Current treatment of inflammatory bowel disease in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Adalimumab treatment in children with refractory Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

Small Intestine Contrast Ultrasonography in Pediatric Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S103

10.1177/03946320140270S103

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774505%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference